These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 8908253)

  • 41. Expression of tumor necrosis factor-like weak inducer of apoptosis in human middle ear cholesteatoma.
    Park M; Lee B; Lee J
    ORL J Otorhinolaryngol Relat Spec; 2013; 75(4):221-7. PubMed ID: 23900149
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Immunohistochemical detection of c-myc proto-oncogene products in middle ear cholesteatoma].
    Holly A; Sittinger M; Bujía J
    Laryngorhinootologie; 1995 Jun; 74(6):348-51. PubMed ID: 7662077
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Alteration of epidermal differentiation in middle ear cholesteatoma.
    Stammberger M; Bujía J; Kastenbauer E
    Am J Otol; 1995 Jul; 16(4):527-31. PubMed ID: 8588655
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Elevated level of tenascin and matrix metalloproteinase 9 correlates with the bone destruction capacity of cholesteatomas.
    Juhász A; Sziklai I; Rákosy Z; Ecsedi S; Adány R; Balázs M
    Otol Neurotol; 2009 Jun; 30(4):559-65. PubMed ID: 19395987
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Role of epithelial cell proliferation and apoptosis in human middle ear cholesteatoma].
    Zhu W; Huang D; Jing L; Zhang F
    Lin Chuang Er Bi Yan Hou Ke Za Zhi; 2001 Jul; 15(7):291-2, 295. PubMed ID: 12541781
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cell cycle inhibitory protein p27 in human middle ear cholesteatoma.
    Kuczkowski J; Bakowska A; Pawelczyk T; Narozny W; Mikaszewski B
    ORL J Otorhinolaryngol Relat Spec; 2006; 68(5):296-301. PubMed ID: 16825801
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immunobiological peculiarities of cholesteatoma in children: quantification of epithelial proliferation by MIB1.
    Bujía J; Holly A; Antolí-Candela F; Tapia MG; Kastenbauer E
    Laryngoscope; 1996 Jul; 106(7):865-8. PubMed ID: 8667984
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Quantitative analysis of interleukin-1-alpha gene expression in middle ear cholesteatoma.
    Bujía J; Kim C; Boyle D; Hammer C; Firestein G; Kastenbauer E
    Laryngoscope; 1996 Feb; 106(2 Pt 1):217-20. PubMed ID: 8583857
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Expression pattern of the plasminogen activator-plasmin system in human cholesteatoma.
    Schönermark MP; Issing PR; Erbrich BK; Lenarz T
    Ann Otol Rhinol Laryngol; 1999 Mar; 108(3):245-52. PubMed ID: 10086616
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Up-regulation of peroxidase proliferator-activated receptor gamma in cholesteatoma.
    Hwang SJ; Kang HJ; Song JJ; Kang JS; Woo JS; Chae SW; Lee HM
    Laryngoscope; 2006 Jan; 116(1):58-61. PubMed ID: 16481810
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [The significance of keratinocyte in hyperproliferation of middle ear cholesteatoma].
    Zhu Z; Hong Y; Wang Y; He G; Ye S
    Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2016 Jan; 30(2):139-43. PubMed ID: 27192911
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [The expression of Ras protein in human middle ear cholesteatoma].
    Xu Y; Jin K; Dong W
    Zhonghua Er Bi Yan Hou Ke Za Zhi; 1999 Apr; 34(2):74-6. PubMed ID: 12764851
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Involvement of interleukin-1 in middle ear cholesteatoma.
    Shiwa M; Kojima H; Kamide Y; Moriyama H
    Am J Otolaryngol; 1995; 16(5):319-24. PubMed ID: 7503375
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cytokeratins in induced epidermoid formations and cholesteatoma lesions.
    Vennix PP; Kuijpers W; Tonnaer EL; Peters TA; Ramaekers FC
    Arch Otolaryngol Head Neck Surg; 1990 May; 116(5):560-5. PubMed ID: 1691647
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cytokeratin patterns of tissues related to cholesteatoma pathogenesis.
    Van Blitterswijk CA; Grote JJ; Lutgert RW; Hesseling SC; Out CJ; Van Muijen GN; Fransen JA
    Ann Otol Rhinol Laryngol; 1989 Aug; 98(8 Pt 1):635-40. PubMed ID: 2475048
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Normal human skin demonstrates marked site-variation of tenascin expression, not correlated to epidermal proliferation (Ki-67 binding).
    Rulo HF; van Vlijmen-Willems IM; Schalkwijk J; Verstraeten AA; van de Kerkhof PC
    J Dermatol Sci; 1993 Feb; 5(1):54-7. PubMed ID: 7683489
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Interleukin-1-containing cells in cholesteatoma of the middle ear].
    Schilling V; Bujia J; Negri B; Kastenbauer E
    Laryngorhinootologie; 1992 May; 71(5):271-5. PubMed ID: 1616549
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Alterations of the basal membrane in middle ear cholesteatoma].
    Bernal Sprekelsen M; Ebmeyer J; Anonopoulos A; Borkowski G; Sudhoff H
    Acta Otorrinolaringol Esp; 2001 May; 52(4):330-5. PubMed ID: 11526629
    [TBL] [Abstract][Full Text] [Related]  

  • 59. HB-EGF expression as a potential biomarker of acquired middle ear cholesteatoma.
    Xie S; Wang X; Ren H; Liu X; Ren J; Liu W
    Acta Otolaryngol; 2017 Aug; 137(8):797-802. PubMed ID: 28498080
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Antigen expression of epithelial markers, collagen IV and Ki67 in middle ear cholesteatoma. An immunohistochemical Study.
    Ergün S; Zheng X; Carlsöö B
    Acta Otolaryngol; 1994 May; 114(3):295-302. PubMed ID: 7521107
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.